The global peptide receptor radionuclide therapy market is anticipated to grow at a significant CAGR during the forecast period (2024-2031). The increasing prevalence of neuroendocrine tumors is expected to impel the demand for peptide receptor radionuclide therapy (PRRT) as an increasing number of the patient pool. The establishment of reimbursement policies for Lutathera favors the demand for peptide receptor radionuclide therapy (PRRT).
Get Free Sample link @ https://www.omrglobal.com/request-sample/peptide-receptor-radionuclide-therapy-market
Moreover, increasing clinical trials for the new radiopharmaceuticals drugs approval for cancer therapy is another factor that is expected to fuel the growth of the global peptide receptor radionuclide therapy (PRRT) market during the forecast period. Increasing government and private organizations funding for cancer drugs and therapy development is another major factor expected to propel the market growth. Moreover, growing manufacturers’ interest in the radiopharmaceutical and cancer market flourish the growth of the global PRRT market.
The global peptide receptor radionuclide therapy market analysis includes some of the key market players and research institutes, such as Novartis AG, ITM Solucin GmbH, National Institutes of Health, Australasian Gastro-Intestinal Trials Group, and Toulouse University Hospital, among others.
Full report of Peptide Receptor Radionuclide Therapy Market available @ https://www.omrglobal.com/industry-reports/peptide-receptor-radionuclide-therapy-market
Market Coverage
- Segment Covered
- Regions Covered- Globally
Competitive Landscape: Novartis AG, ITM Solucin GmbH, National Institutes of Health, Australasian Gastro-Intestinal Trials Group, and Toulouse University Hospital, among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominates the market in base year?
- Which segment and region will project fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Peptide Receptor Radionuclide Therapy Market by Segment
By Drug Type
- Lutetium (Lu-177)-based)
By Disease Indication
- Pancreatic – Neuroendocrine Tumor
- Gastrointestinal Tract – Neuroendocrine Tumor
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online
Reasons to Buying From us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/peptide-receptor-radionuclide-therapy-market
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
